FINWIRES · TerminalLIVE
FINWIRES

アビティビ・メタルズは、ディスカバリー・シルバーが主導する非仲介型資金調達により3,080万ドルを調達し、戦略的株式の9.9%を取得する。

-- アビティビ・メタルズ(AMQ.CN)は木曜日、最大3,080万ドルの非仲介型私募増資を発表した。 同社によると、ディスカバリー・シルバーは、この増資完了時に、発行済み普通株式の約9.9%を希薄化なしで取得する予定である。増資完了に伴い、アビティビ・メタルズとディスカバリーは参加契約を締結し、一定の条件の下、ディスカバリーが同社への出資持分およびその他の慣習的な投資家権利を維持できるよう、アビティビ・メタルズは一定の資金調達権およびその他の参加権を付与する。 今回の増資は、1株当たり0.85ドルのチャリティ・フロー・スルー(CFT)普通株式1,180万株と、1株当たり0.58ドルのハード・ダラー(HD)普通株式3,580万株の組み合わせで構成され、総額最大3,080万ドルの資金調達が見込まれる。 CFT株の発行による収益は、ケベック州を拠点とするプロジェクトにおける適格な「カナダ探査費用」に充当され、これは「フロー・スルー鉱業支出」として認められる予定です。HD株の発行による純収益は、探査・開発活動および一般的な企業運営資金に充当される予定です。 同社の株価は水曜日、カナダ証券取引所で4.2%上昇し、0.74ドルで取引を終えました。

Related Articles

Asia

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

$ASX:ONE
Asia

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

$ASX:PAR
Asia

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

$SHA:600703